StockNews.AI
CVAC
StockNews.AI
145 days

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

1. EPO confirms validity of CureVac's patent EP 3 708 668 B1. 2. Patent affirmation supports CureVac's mRNA innovation amid BioNTech's opposition.

2m saved
Insight
Article

FAQ

Why Bullish?

The confirmation of CureVac's patent reinforces its competitive position in mRNA technology, similar to how Moderna's patent confirmations positively impacted its stock following legal disputes.

How important is it?

The validation of the patent is crucial for CVAC's market valuation and future developments, enhancing investor confidence.

Why Long Term?

Long-term growth expected as patent confirms CureVac's position in mRNA development, similar to Pfizer's sustained growth post-patent victories.

Related Companies

BNTXMRNAPFE
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A hearing on infringement of EP 3 708 668 B1 is scheduled for July 1, 2025, before the Regional Court Düsseldorf Confirming validity of patent in its amended form marks major milestone in broader patent litigation in Germany, recognizing CureVac's pioneering mRNA innovation TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / March 27, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the European Patent Office (EPO) has confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection.

Related News